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Introduction {#ner12930-sec-0007}
============

Essential tremor (ET) is one of the most common movement disorders, occurring in 1 out of every 25 people aged 40 years or older, and is estimated to affect up to 7 million people in the United States [1](#ner12930-bib-0001){ref-type="ref"}, [2](#ner12930-bib-0002){ref-type="ref"}, [3](#ner12930-bib-0003){ref-type="ref"}. A majority of ET patients exhibit a postural and kinetic tremor in the upper limbs, and less commonly exhibit tremor of the head, face, voice, trunk, and lower limbs, all of which can impair daily activities [4](#ner12930-bib-0004){ref-type="ref"}, [5](#ner12930-bib-0005){ref-type="ref"}. Current first‐line pharmacologic treatment options for ET, including propranolol and primidone, are often limited by inadequate effectiveness or intolerable side effects [6](#ner12930-bib-0006){ref-type="ref"}. Tremor symptoms are poorly treated or refractory to first‐line treatment options in an estimated 25%‐55% of patients [7](#ner12930-bib-0007){ref-type="ref"}, [8](#ner12930-bib-0008){ref-type="ref"}.

Though the exact mechanisms are uncertain, ET arises from oscillatory activity within a central tremor network, which involves the ventral intermediate nucleus (VIM) of the thalamus [6](#ner12930-bib-0006){ref-type="ref"}, [9](#ner12930-bib-0009){ref-type="ref"}, [10](#ner12930-bib-0010){ref-type="ref"}. Evidence supports targeting the VIM to treat tremor symptoms in ET patients using methods including deep brain stimulation (DBS), surgical ablation, gamma knife ablation, and focused ultrasound [11](#ner12930-bib-0011){ref-type="ref"}, [12](#ner12930-bib-0012){ref-type="ref"}, [13](#ner12930-bib-0013){ref-type="ref"}. DBS of the VIM is highly effective for tremor suppression, with a reported 68 to 89% reduction in tremor [14](#ner12930-bib-0014){ref-type="ref"}, [15](#ner12930-bib-0015){ref-type="ref"}, [16](#ner12930-bib-0016){ref-type="ref"}, but implantation of the stimulation leads and pulse generator requires an invasive surgical procedure with associated risks [17](#ner12930-bib-0017){ref-type="ref"}, [18](#ner12930-bib-0018){ref-type="ref"}. Only a small fraction of ET patients who are candidates for DBS surgery receive an implant for various reasons [19](#ner12930-bib-0019){ref-type="ref"}. Previous studies have shown electrical median nerve stimulation evokes activity within the VIM and other regions of the central tremor network [20](#ner12930-bib-0020){ref-type="ref"}, [21](#ner12930-bib-0021){ref-type="ref"}, and that electrical stimulation of these pathways in a synchronized pattern can decrease tremor [22](#ner12930-bib-0022){ref-type="ref"}, [23](#ner12930-bib-0023){ref-type="ref"}. Based on these observations, we hypothesized that median and radial nerve stimulation at the wrist may reduce hand tremor.

Lin et al. recently reported reductions in hand tremor following noninvasive median and radial nerve stimulation in a small cohort of individuals with ET evaluated at a single site [24](#ner12930-bib-0024){ref-type="ref"}. In the current study, we investigated the effect of noninvasive median and radial nerve stimulation in a larger cohort of subjects in a prospective, randomized, sham controlled trial to further assess the safety and effectiveness of a wrist‐worn peripheral nerve stimulation device for treatment of hand tremors in adults with ET.

Methods {#ner12930-sec-0008}
=======

Participants {#ner12930-sec-0009}
------------

This study was conducted at four sites (see acknowledgements for list of sites). Of the 111 subjects who were screened, 93 subjects (mean age 70.2 ± 10.6 years, 45 males) were randomized to receive either treatment (*N* = 48) or sham stimulation (*N* = 45; Fig. [1](#ner12930-fig-0001){ref-type="fig"}; Table [1](#ner12930-tbl-0001){ref-type="table"}). Subjects who were already taking medications for ET were required to remain on their medications during the study with no changes in medication type or dosage. Key inclusion criteria were 1) at least 22 years of age; 2) diagnosis of ET as confirmed from clinical history and examination by a movement disorder neurologist; 3) signed informed consent; 4) at least one hand exhibiting score ≥2 as assessed by the Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS) Archimedes spiral task completed during the baseline evaluation, as assessed by the investigator in‐person; and 5) score of 3 or above in any 1 of the items of the Bain and Findley activities of daily living (ADL) scale. Key exclusion criteria were 1) implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator; 2) history of thalamotomy; 3) suspected or diagnosed epilepsy or other seizure disorder; 4) pregnancy; 5) skin lesions at stimulation site; 6) peripheral neuropathy; 7) alcohol dependence; 8) other possible causes of tremor; 9) neurologic exam not consistent with ET; 10) alcohol or caffeine consumption within 12 hours of study enrollment. ET medications were stable for 1 month before enrollment. Based on prespecified inclusion criteria of a baseline TETRAS spiral rating of ≥2 as assessed by the average score from three blinded central raters, 77 subjects were included in the effectiveness analysis population (EAP).

![Flow diagram of the study selection.](NER-22-537-g001){#ner12930-fig-0001}

###### 

Subject Demographic and Baseline Severity Information.

  Demographic                                      Overall (*N* = 93)   Treatment (*N* = 48)   Sham (*N* = 45)
  ------------------------------------------------ -------------------- ---------------------- -----------------
  Age----y                                         70.2 ± 10.6          70.5 ± 11.2            69.8 ± 10.1
  Male sex----no. (%)                              45 (48)              23 (48)                22 (49)
  Race----no. (%)                                                                              
  White                                            88 (95)              47 (98)                41 (91)
  Asian                                            1 (1)                0                      1 (2)
  Black or African American                        0                    0                      0
  More than one race                               3 (3)                1 (2)                  2 (4)
  Onset and Diagnosis----y                                                                     
  Age of onset                                     38.8 ± 21.2          41.1 ± 22.2            36.2 ± 20.0
  Age of diagnosis                                 52.8 ± 15.0          53.5 ± 15.4            52.1 ± 14.6
  Family history of ET----no. (%)                  72 (77)              38 (79)                34 (76)
  Current tremor co‐therapy----no. (%)                                                         
  None                                             36 (39)              17 (35)                19 (42)
  1 medication                                     32 (34)              16 (33)                16 (36)
  \> 1 medication                                  25 (27)              15 (31)                10 (22)
  Current tremor medications----no. (%)                                                        
  Propranolol                                      41 (44)              25 (52)                16 (36)
  Primidone                                        22 (24)              13 (27)                9 (20)
  Other                                            19 (20)              9 (19)                 10 (22)
  Duration of current tremor medications----y      8.2 ± 9.0            8.5 ± 8.3              7.8 ± 9.8
  Prior treatments of ET----no. (%)                                                            
  Medication                                       54 (58)              25 (52)                29 (64)
  Botulinum toxin                                  4 (4.3)              3 (6.3)                1 (2.2)
  Other                                            3 (3.2)              2 (4.2)                1 (2.2)
  Bain and Findley ADLs                                                                        
  Hand subset (range: 7‐28)                        16.1 ± 4.1           16.7 ± 4.0             15.5 ± 4.1
  Total score (range: 25‐100)                      45.4 ± 9.6           45.8 ± 9.0             45.0 ± 10.3
  TETRAS performance subscale                                                                  
  Archimedes spiral, TETRAS task 6 (range: 0‐4)    2.6 ± 0.7            2.7 ± 0.8              2.5 ± 0.6
  Upper limb tremor, TETRAS task 4 (range: 0‐12)   6.1 ± 1.6            6.3 ± 1.4              6.0 ± 1.7
  Total score (range: 0‐64)                        25.3 ± 6.0           25.8 ± 6.0             24.8 ± 6.0

Standard Protocol Approvals, Registrations, and Patient Consent {#ner12930-sec-0010}
---------------------------------------------------------------

The clinical investigational protocol and subject informed consent form for this study were reviewed and approved by an Institutional Review Board for each clinical site prior to study initiation. Written informed consent was obtained from all subjects prior to study participation. This study was registered in [ClinicalTrials.gov](http://clinicaltrials.gov) as study number NCT02629614.

Cala ONE Device Fitting, Calibration, and Stimulation Delivery {#ner12930-sec-0011}
--------------------------------------------------------------

Following randomization, all subjects were fitted with a Cala ONE device based on the subject\'s therapy allocation (treatment or sham), wrist circumference (small circumference: 13.5‐15.4 cm, medium: 15.5‐17.4 cm, large 17.5‐19.5 cm), and stimulation hand (right or left). No skin preparation was required prior to application of the device, although subjects were asked to avoid lotion application prior to testing. The stimulation hand was the hand with more severe tremor (or the dominant hand if both hands had equal tremor severity) as determined by the TETRAS Archimedes spiral task completed during the baseline evaluation and assessed in‐person by the study investigator. Cala ONE working electrodes were placed over the median and radial nerves on the anterior surface of the wrist, while a single counter‐electrode was located on the posterior surface of the wrist (Fig. [2](#ner12930-fig-0002){ref-type="fig"}a). The electrodes were 2.2 cm × 2.2 cm square hydrogel electrodes spaced according to wrist circumference (small: 1.3 cm between electrodes; medium: 1.8 cm between electrodes; large: 2.3 cm between electrodes). Once the appropriate Cala ONE device was fitted to the subject\'s hand, the device performed a frequency calibration procedure during which the device measured the subject\'s tremor frequency while the subject performed a forward postural hold task (Fig. [2](#ner12930-fig-0002){ref-type="fig"}b). This frequency was then incorporated into the stimulation waveform (Fig. [2](#ner12930-fig-0002){ref-type="fig"}c). Stimulation consisted of a series of charge balanced biphasic pulses, 300 μs biphasic pulses, with a 50 μs interpulse period between pulses, delivered at a frequency of 150 Hz. The stimulation alternated between the median and radial nerve at a frequency equal to tremor frequency as measured by on‐board accelerometers (for example, for a measured 5 Hz tremor frequency, stimulation was applied over the median nerve for 100 msec and then was applied over the radial nerve for 100 msec). Both treatment and sham subjects were exposed to the frequency calibration procedure and to stimulation during an amplitude calibration period, during which study personnel increased the stimulation level by 0.25 mA steps until the subject reported first perceived sensation in the hand or finger area corresponding to distributions of the palmar digital branches of the median nerve and the superficial branch of the radial nerve. Final stimulation amplitude was chosen to be the highest level of tolerable stimulation level (always below muscle contraction) that the subject found comfortable (mean: 5.4 mA ± 2.9). Once final stimulation amplitude was identified, treatment subjects received stimulation at that level during a 40‐minute stimulation session, while sham subjects received no stimulation. Subjects were blinded to whether they were randomized to receive treatment stimulation or sham stimulation. During the stimulation session subjects could request the stimulation amplitude be decreased or discontinued for any reason.

![Cala ONE device and study design. a. Electrode placement on subject\'s wrist to target median and radial nerves, with counter‐electrode positioned on posterior surface of the wrist. b. Subject tremor frequency is captured during a 20 seconds postural hold (middle 10 seconds recorded by the device). The peak tremor frequency is determined on‐board the device and is input into the stimulation waveform to deliver a subject‐specific stimulation. c. Waveform consists of a series of charge balanced biphasic pulses delivered at a frequency of 150 Hz, 300 μs pulse width, and 50 μs interpulse period alternating between the median and radial nerve at a frequency equal to the tremor frequency. d. TETRAS and ADL scores were collected before and after treatment or sham stimulation sessions, and CGI was collected after the session. Both groups underwent the same frequency calibration and stimulation amplitude setting. Treatment consisted of a ramp up of stimulation (typically 1‐2 minutes) followed by a 40‐minute stimulation, whereas sham included a ramp up of 1 minute followed by a rapid ramp down of the stimulation. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](NER-22-537-g002){#ner12930-fig-0002}

Study Outcome Measures {#ner12930-sec-0012}
----------------------

The primary effectiveness measure was predefined as improvement in tremor severity in the dominant hand as measured by the TETRAS task 6 Archimedes spiral score following stimulation compared to sham stimulation for the treated limb. This measure was chosen based on a pilot study which showed a significant improvement in this parameter relative to sham [24](#ner12930-bib-0024){ref-type="ref"}. Secondary effectiveness measurements included a subject self‐reported assessment of improvement with the clinical global impressions scale of improvement (CGI‐I) scale. Additional effectiveness endpoints included improvement in TETRAS task 4 upper limb subscores for the treated limb tremor tasks after stimulation, as well as improvement in a subset of Bain and Findley ADLs collected in the office as measured by subject ratings. The effectiveness analyses included only enrolled subjects who met the predefined EAP criteria of having a baseline TETRAS task 6 Archimedes spiral rating ≥ 2, as assessed by average score from the three blinded raters, as predetermined in the study. Percent tremor amplitude reduction was calculated from TETRAS and ADL scores from baseline as described by Elble et al. (*α* = 0.5) [25](#ner12930-bib-0025){ref-type="ref"}, [26](#ner12930-bib-0026){ref-type="ref"}. The primary safety endpoint was an analysis of adverse events types and rates for all enrolled subjects, where the adverse event rate was calculated as the percentage of total subjects with an adverse event.

Tremor Rating Assessments {#ner12930-sec-0013}
-------------------------

TETRAS ratings were used to assess the effect of stimulation on the treated limb. The TETRAS Archimedes spiral task 6 requires subjects to draw a spiral drawing in a 10‐cm sized square. Spirals were rated on the five‐point (0‐4) TETRAS scale with 0.5‐point resolution (0 = normal, 1 = slight: tremor barely visible, 2 = mild: obvious tremor, 3 = moderate: portions of figure not recognizable, 4 = severe: figure not recognizable). The TETRAS upper limb tremor task 4 assessment included three tasks to assess tremor severity: forward outstretched posture, lateral "wing beating" posture, and kinetic finger‐nose‐finger testing. Each upper limb was assessed and scored individually by the investigator using the following 5‐point (0‐4) TETRAS rating scale: 0 = no tremor, 1 = tremor is barely visible, 1.5 = tremor is visible, but less than 1 cm, 2 = tremor is greater than 1 cm but less than 3 cm amplitude, 2.5 = tremor is greater than 3 cm but less than 5 cm amplitude, 3 = tremor is greater than 5 cm but less than 10 cm amplitude, 3.5 = tremor is greater than 10 cm but less than 20 cm amplitude, 4 = tremor is greater than 20 cm amplitude.

A subset of 7 Bain and Findley ADL tasks that could be performed unilaterally (using one hand), which did not require the dominant hand were performed by the subject at baseline and after the session to evaluate functional improvements in ADLs with stimulation. These tasks included using a spoon to drink soup, holding a cup of tea, pouring milk from a bottle, dialing a phone, picking up change, inserting a plug into a socket, and unlocking a door with a key. The subjects (blinded as to whether they received stimulation or sham) performed the tasks and rated themselves from 1 to 4 on the following Bain and Findley ADL scale: 1 = able to do the activity without difficulty, 2 = able to do the activity with a little effort, 3 = able to do the activity with a lot of effort, 4 = cannot do the activity by yourself. Finally, subjects rated themselves using the CGI‐I scale, which is a seven‐point self‐report scale that required the subject to assess how much their tremor level has improved or worsened relative to their baseline state: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. All subjects performed baseline tremor assessments prior to and immediately following a 40‐minute session with the Cala ONE treatment or sham device (Fig. [2](#ner12930-fig-0002){ref-type="fig"}d). Adverse events were collected before, during, and after the stimulation session.

Blinding {#ner12930-sec-0014}
--------

Subjects and independent raters who provided the ratings for the primary effectiveness endpoint were blinded to therapy allocation. Raters were unblinded to TETRAS upper limb tremor outcome measures. Subjects were blinded throughout the study and during all ratings (including ADL, and CGI‐I ratings). To maintain the blind, all subjects were informed that they "may or may not feel stimulation" during the 40‐minute stimulation session. Visual cues on the device were used to maintain the blind, including a countdown during stimulation shown on the device display. Blinding was assessed with a subject blinding questionnaire after device removal.

Randomization {#ner12930-sec-0015}
-------------

Subjects were randomized 1:1 to receive the investigational patterned stimulation ("treatment" group) or sham stimulation ("sham" group). The therapy allocation for each subject was determined at the time of enrollment using a randomization approach stratified by site such that therapy allocation was balanced within site. Prior to study initiation, randomization lists were provided by Agility Clinical Corp. for up to five sites, block randomization, with seven blocks of size 6. Within each block, three subjects were randomized to treatment and three to sham stimulation. The order of the spiral images was randomized so that the independent raters were blinded to whether the spirals were before or after treatment and whether a subject was in the treatment group or sham group.

Statistical Analysis {#ner12930-sec-0016}
--------------------

Statistical analyses were predefined in the statistical analysis plan for this study. An analysis of covariance (ANCOVA) model was used to assess the statistical significance of the difference in the mean change between the treatment and sham groups for the primary endpoint which was defined as the change in TETRAS Archimedes spiral drawing score following stimulation. The model included the baseline score for the task as a continuous covariate, and randomization assignment as a classification variable. For secondary endpoints, the statistical significance of the differences in the mean change between the treatment and the sham groups after stimulation was assessed using two‐sample, two‐tailed *t*‐tests for each individual TETRAS and ADL task as well as for the difference in the composite scores. Changes in CGI‐I between treatment and sham groups were tested for statistical significance using the Wilcoxon Rank Sum test. For all tests, a *p*‐value of \<0.05 was considered statistically significant.

Results {#ner12930-sec-0017}
=======

Physician‐Rated Metrics {#ner12930-sec-0018}
-----------------------

There was not a significantly larger improvement in the Archimedes spiral rating in treatment (0.55) compared to sham (0.41) (*p* = 0.26). However, upper limb tremor task 4 TETRAS subscores for the treated limb showed that there was a significantly greater improvement following treatment stimulation compared to sham stimulation. Of the individual improvement in TETRAS scores for subjects following treatment or sham stimulation, there was a significant improvement in forward postural hold rating in the treatment group (0.75) compared to sham (0.35) (*p* = 0.004) (Fig. [3](#ner12930-fig-0003){ref-type="fig"}a), a 46% reduction in tremor amplitude with treatment compared to 24% reduction in tremor amplitude with sham. The average improvement in the treated hand TETRAS upper limb tremor task 4 for treatment (0.61) compared to sham (0.35; *p* = 0.017; Fig. [3](#ner12930-fig-0003){ref-type="fig"}b), a 42% reduction in tremor amplitude with treatment compared to 28% reduction with sham. The total TETRAS performance score (tasks 4 and 6) showed a significant improvement for treatment (2.38) compared to sham (1.45; *p* = 0.015) (Fig. [3](#ner12930-fig-0003){ref-type="fig"}c).

![TETRAS improvement with stimulation. a. Average improvement for subjects following treatment (*N* = 40) or sham (*N* = 37) stimulation by individual TETRAS Archimedes spiral drawing (task 6) and individual upper limb tremor tasks (task 4). b. TETRAS dominant combined upper limb tremor task (task 4) (*p* = 0.017). c TETRAS performance subscore (tasks 4 and 6). \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](NER-22-537-g003){#ner12930-fig-0003}

Subject‐Rated Metrics {#ner12930-sec-0019}
---------------------

In the Bain and Findley ADLs that were performed and rated by subjects, treatment subjects showed a significant improvement following stimulation compared to sham in tasks including holding a cup of tea (1.03 vs. 0.57; *p* = 0.011), dialing a telephone (0.70 vs. 0.30; *p* = 0.015), picking up change (0.53 vs. 0.05; *p* = 0.002), and unlocking a door with a key (0.6 vs. 0.17; *p* = 0.010); however, tasks including using a spoon to drink soup, pouring milk from a bottle, and inserting a plug into a socket were not significant compared to sham (Table [2](#ner12930-tbl-0002){ref-type="table"}, Fig. [4](#ner12930-fig-0004){ref-type="fig"}a). Of note, the treatment group improved significantly compared to baseline on all seven activities (all *p*‐values \<0.05). The sham group improved significantly compared to baseline for five of the seven activities (using a spoon to drink soup, holding a cup of tea, pouring milk from a bottle or carton, dialing a telephone, and inserting an electric plug into a socket). Treatment improved ADLs across all measured tasks by 0.66 while sham improved by 0.36 (*p* = 0.001) (Fig. [4](#ner12930-fig-0004){ref-type="fig"}b), a 49% improvement with treatment compared to a 27% improvement in tremor amplitude with sham.

###### 

Bain and Findley Activities of Daily Living.

                                          Treatment      Sham                          
  --------------------------------------- -------------- -------------- -------------- --------------
  Use a spoon to drink soup               3.18 ± 0.12    −0.78 ± 0.14   3.00 ± 0.14    −0.59 ± 0.13
  Hold a cup of tea                       2.95 ± 0.13    −1.03 ± 0.12   2.65 ± 0.15    −0.57 ± 0.13
  Pour milk from a bottle or carton       2.78 ± 1.16    −0.70 ± 0.12   2.59 ± 0.14    −0.59 ± 0.12
  Dial a telephone                        2.23 ± 0.14    −0.70 ± 0.13   2.00 ± 0.15    −0.30 ± 0.10
  Pick up your change in a shop           2.03 ± 0.14    −0.53 ± 0.11   1.92 ± 0.15    −0.05 ± 0.10
  Insert an electric plug into a socket   1.83 ± 0.12    −0.33 ± 0.11   1.76 ± 0.13    −0.24 ± 0.09
  Unlock your front door with a key       2.23 ± 0.14    −0.60 ± 0.14   1.86 ± 0.11    −0.16 ± 0.09
  ADL subset total                        17.20 ± 0.65   −4.65 ± 0.44   15.78 ± 0.64   −2.51 ± 0.45

![Subject‐rated Bain and Findley activities of daily living improvement with stimulation. a. Average improvement for subjects following treatment (*N* = 40) or sham (*N* = 37) stimulation as rated by blinded subjects using the Bain and Findley activities of daily living subscale. b. Average improvement across activities (*p* = 0.001). (Mean ± SEM) \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](NER-22-537-g004){#ner12930-fig-0004}

Treatment subjects reported improvement in the CGI‐I scale that was significantly greater than sham (*p* = 0.019. CGI‐I scores showed that a greater percentage of subjects in the treatment group reported an improvement after stimulation, which was a significant improvement compared to the sham group. The mean poststimulation rating on CGI‐I was 2.65 (between minimally and much improved) for the treatment group compared to 3.14 (between no change and minimally improved) for the sham group. Overall, 88% of treated subjects reported improvement in their tremor in the treatment group while 62% of sham subjects reported improvement (Fig. [5](#ner12930-fig-0005){ref-type="fig"}).

![Clinical global impression of improvement scale. The clinical global impression‐improvement scale is a self‐report scale that required the subject to assess how much their tremor level has improved or worsened relative to their baseline state prior to the session. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](NER-22-537-g005){#ner12930-fig-0005}

Blinding assessment showed a blinding index of 0.608 (95% CI: 0.509‐0.708), which indicated a successful blind (0.5 indicates random guessing) [27](#ner12930-bib-0027){ref-type="ref"}. This index is a numerical assessment of how well a study blind was maintained [27](#ner12930-bib-0027){ref-type="ref"}.

Safety {#ner12930-sec-0020}
------

No significant adverse events or unanticipated adverse device effects were reported in the study. The adverse event rate was low at 3% (two subjects in the treatment group and one subject in the sham group). Observed adverse events included significant and persistent skin irritation (including redness, itchiness, and/or swelling) in two subjects who received treatment and sensation of weakness or stinging pain in the wrist in one subject who received treatment stimulation and one subject who received sham stimulation. All adverse events were mild and resolved within 24 hours without treatment or sequelae. No subjects in this study requested reduction or cessation of stimulation.

Discussion {#ner12930-sec-0021}
==========

This study evaluated the safety and effectiveness of a single session of peripheral stimulation of the median and radial nerves on hand tremor symptoms in ET patients. Although the primary endpoint was not met, multiple other endpoints were met. The primary endpoint was specified following a small randomized blinded pilot study that demonstrated a significant difference between treatment and sham measured by the TETRAS Archimedes spiral [24](#ner12930-bib-0024){ref-type="ref"}. In the current multisite study, the spirals were not statistically different between treatment and sham because both were significantly improved from baseline. The large sham effect observed in this study is not surprising given the large effect of sham simulation observed in other studies, particularly in neurologic device studies [28](#ner12930-bib-0028){ref-type="ref"}, [29](#ner12930-bib-0029){ref-type="ref"}. The TETRAS Archimedes spiral rating is a single measure of tremor, and it does not encompass all aspects of hand tremor. Broader measures of tremor in this study showed a significant improvement compared to sham.

The treatment group experienced significantly greater improvements than the sham group in functional outcome measures (TETRAS upper limb tremor scores and ADLs) as well as patient reported outcomes (CGI‐I scores), which are meaningful to both patients and physicians. The magnitude of the improvement in the tasks in the treatment corresponded to a 49% reduction in tremor according to ADLs, and a 42% reduction according to TETRAS upper limb tremor following a single stimulation session [25](#ner12930-bib-0025){ref-type="ref"}, [26](#ner12930-bib-0026){ref-type="ref"}. These improvements are clinically meaningful, and within the range of tremor amplitude improvement (32%‐75%) reported in controlled studies of the medications most commonly prescribed for ET [26](#ner12930-bib-0026){ref-type="ref"}. Additionally, 75% of subjects had a response greater than 30% improvement, and 65% of subjects had a response greater than 40% improvement in TETRAS following a single stimulation session. Further, 70% of subjects reported a greater than 30% improvement in ADLs, and 65% of subjects reported a greater than 40% improvement.

ET continues to cause disabling tremor in a large number of patients who have tried oral medications and are either not candidates for surgical or other invasive interventions, or do not want to consider surgical or invasive interventions. While there have been studies investigating alternative nontherapeutic solutions to aid in specific ADLs, including the use of a real‐time control prosthetic tool, utility is currently limited to eating [30](#ner12930-bib-0030){ref-type="ref"}. The observed response in this study was achieved without the risks of surgical or pharmacologic intervention, such as the risk of hemorrhage (5% reported rate) or infection (4% reported rate) with DBS implantation or other invasive procedures [13](#ner12930-bib-0013){ref-type="ref"}, [31](#ner12930-bib-0031){ref-type="ref"}, [32](#ner12930-bib-0032){ref-type="ref"}, or side effects from ET medications [33](#ner12930-bib-0033){ref-type="ref"}. One of the more recent invasive FDA approved therapies to treat hand tremor in ET patients is focused ultrasound thalamotomy. While focused ultrasound thalamotomy is demonstrated to significantly reduce hand tremor (47% reduction after 3 months), Elias et al. reported the significant adverse event profile of 56 subjects who received thalamotomy; these adverse events included gait disturbance in 36% of patients and paresthesias or numbness in 38% of patients [13](#ner12930-bib-0013){ref-type="ref"}. Although the current study investigated the safety profile following a single stimulation session, there were no serious adverse events, and only 3% of subjects reported adverse events that spontaneously resolved within 24 hours without intervention. This side effect profile is encouraging and may provide an additional treatment option for patients who are interested in a treatment with a more limited side effect profile than current therapy options.

It is important to acknowledge the limitations of this study. First, this study was performed with a small group of subjects in whom safety and effectiveness were evaluated immediately after stimulation in a single in clinic session. As a result, we were unable to measure the effect of stimulation over time or implement automated tools to detect tremor in real‐time to optimize therapy. Future studies should investigate the durability of the therapeutic effect and the effects of chronic use with enabling technologies to automate tremor measurement over time [34](#ner12930-bib-0034){ref-type="ref"}, [35](#ner12930-bib-0035){ref-type="ref"}, [36](#ner12930-bib-0036){ref-type="ref"}. Since the device is worn on the wrist, there is potential to incorporate kinematic measurements to provide feedback regarding tremor burden over time to patients and clinicians. Further, due to the immediate therapeutic effect of stimulation, which is unlike other available pharmacologic interventions, kinematic measurements may provide insight into the effect of stimulation on tremor amplitude over time.

This therapeutic approach was inspired by the observation that peripheral stimulation evokes central activity in brain regions such as the VIM, a target that when effectively stimulated with DBS can improve tremor [18](#ner12930-bib-0018){ref-type="ref"}. While the success of the patterned peripheral nerve stimulation tested here is consistent with this hypothesis, other potential mechanisms are possible, including circuitry modulated in previous studies demonstrating tremor reduction by manipulation of sensory input, including with topical anesthesia, cooling, vibration, and electrical stimulation [37](#ner12930-bib-0037){ref-type="ref"}, [38](#ner12930-bib-0038){ref-type="ref"}, [39](#ner12930-bib-0039){ref-type="ref"}, [40](#ner12930-bib-0040){ref-type="ref"}. It is also possible that alternative stimulation methods may improve tremor in patients with ET, and determination of optimal treatment for each patient requires further research.

Overall, our data suggest that the subjects who received patterned treatment stimulation experienced a significant reduction in tremor and an improvement in function. These results are encouraging, and future studies are needed to confirm the effectiveness of this noninvasive therapy over time.
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COMMENT {#ner12930-sec-1015}
=======

This study assesses a novel, short‐term peripheral nerve stimulation method to reduce tremor and improve hand function. Further studies may extend the usefulness of this non‐invasive approach for longer‐term symptomatic tremor control, particularly if a feedback system can be developed to modulate the intensity of the stimulation directly in relation to tremor amplitude.
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